Alnylam Pharmaceuticals experienced a stock jump after receiving a second Food and Drug Administration approval for its drug, Amvuttra, now indicated for cardiomyopathy. This approval opens a significantly larger market compared to its previous approval for transthyretin amyloid polyneuropathy.
Amvuttra differentiates itself from competitors Pfizer’s Vyndaqel and BridgeBio Pharma’s Attruby by offering a treatment regimen involving shots every six months, as opposed to daily pills. Analysts anticipate strong uptake of Amvuttra due to its efficacy and safety profile.
Alnylam retained the annual price of $477,000 for Amvuttra in the cardiomyopathy market, which is nearly double the cost of Vyndaqel and Attruby. Despite the pricing premium, analysts believe the market is large enough for all three drugs. Rising diagnosis rates and Amvuttra’s favorability among younger and healthier cardiomyopathy patients position it well for first-line usage.
However, some analysts warn of potential headwinds due to Amvuttra’s high pricing compared to alternatives.
— news from Investor’s Business Daily